
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. has garnered a positive outlook due to significant regulatory progress for its OST-HER2 treatment, which has been elevated to a Type B pre-BLA meeting by the FDA, indicating a strong alignment towards potential Accelerated Approval. The company's successful Phase 2b trial data demonstrating statistically significant improvements in event-free survival and overall survival in pulmonary metastatic osteosarcoma further supports its development efforts and potential market viability. Additionally, the multiple regulatory designations for OST-HER2, including orphan and fast track status, are anticipated to expedite its review process, enhancing OS Therapies' strategic positioning as it approaches its planned submission and targets for accelerated market access by late 2026.
Bears say
OS Therapies Inc's financial report reveals a significant increase in operating loss, rising to $28.75 million in 2025 from $8.82 million in 2024, highlighting a growing burden from development and regulatory expenses. This escalating cost structure raises concerns about the company's financial sustainability as it attempts to advance its pipeline of product candidates. Furthermore, the heightened expenditure on broader corporate infrastructure may limit available resources for critical research and development, negatively impacting the firm’s future growth prospects.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares